Michael John Sumner
Known title: Chief Medical OfficerCIK: 0001936799
Associated companies
Transaction History
| INO | ▲ Buy | Option Exercise | 9,450 | — | 5/20/2026 | View on chart |
| INO | ▼ Sell | Tax Withholding | 2,693 | $3K | 5/20/2026 | View on chart |
| INO | ▼ Sell | Tax Withholding | 680 | $884 | 5/15/2026 | View on chart |
| INO | ▲ Buy | Option Exercise | 2,385 | — | 5/15/2026 | View on chart |
| INO | ▲ Buy | Option Exercise | 4,292 | — | 3/31/2026 | View on chart |
| INO | ▼ Sell | Tax Withholding | 1,223 | $2K | 3/31/2026 | View on chart |
| INO | ▲ Buy | Option Exercise | 5,010 | — | 2/26/2026 | View on chart |
| INO | ▲ Buy | Option Exercise | 11,550 | — | 2/26/2026 | View on chart |
| INO | ▼ Sell | Tax Withholding | 3,903 | $7K | 2/26/2026 | View on chart |
| INO | ▲ Buy | Option Exercise | 2,916 | — | 6/30/2025 | View on chart |
| INO | ▲ Buy | Option Exercise | 2,385 | — | 5/15/2025 | View on chart |
| INO | ▼ Sell | Tax Withholding | 680 | $1K | 5/15/2025 | View on chart |
| INO | ▲ Buy | Option Exercise | 5,010 | — | 2/26/2025 | View on chart |
| INO | ▲ Buy | Option Exercise | 2,917 | — | 6/30/2024 | View on chart |
| INO | ▲ Buy | Option Exercise | 2,386 | — | 5/15/2024 | View on chart |
| INO | ▲ Buy | Option Exercise | 35,000 | — | 6/30/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
INO: PGEN AdenoVerse Pipeline May Drive Growth Beyond Papzimeos
The article examines whether PGEN’s AdenoVerse platform can generate growth that surpasses the company’s current Papzimeos product line. It highlights the potential of the pipeline to broaden Inovio’s therapeutic offerings. The discussion comes as the stock sits near its 16‑touch support level of $1.07 and a neutral RSI of 45.6. Analysts still target the shares at around $3.17 on average.
INO: PGEN AdenoVerse Pipeline May Drive Growth Beyond Papzimeos. The article examines whether PGEN’s AdenoVerse platform can generate growth that surpasses the company’s current Papzimeos product line. It highlights the potential of the pipeline to broaden Inovio’s therapeutic offerings. The discussion comes as the stock sits near its 16‑touch support level of $1.07 and a neutral RSI of 45.6. Analysts still target the shares at around $3.17 on average.